Fig. 3: Comorbidities at baseline among patients living with obesity compared to patients living without obesity in each database, stratified by COVID-19 cohort type (diagnosed and hospitalized). | International Journal of Obesity

Fig. 3: Comorbidities at baseline among patients living with obesity compared to patients living without obesity in each database, stratified by COVID-19 cohort type (diagnosed and hospitalized).

From: Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

Fig. 3

Prevalence of comorbidities for COVID-19 patients living with obesity (red) and without obesity (blue) are depicted in overlapped horizontal bars. The gray color is the overlap between groups. E.g., in CPRD, 32% of COVID-19 patients living with obesity and 16% living without obesity have hypertension. Comorbidities with a meaningful difference (|SMD| > 0.1) between patients living with and without obesity are marked with an asterisk (*). COPD chronic obstructive pulmonary disease, COVID-19 coronavirus disease 2019, CPRD Clinical Practice Research Datalink, CUIMC Columbia University Irving Medical Center, SIDIAP Information System for Research in Primary Care, SMD standardized mean difference, STARR-OMOP Stanford Medicine Research Data Repository, VA-OMOP United States Department of Veterans Affairs.

Back to article page